Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction: Gout is a common arthritis that occurs particularly in patients who frequently have associated comorbidities that limit the use of conventional therapies. The main mechanism of crystal-induced inflammation is interleukin-1 production by activation of the inflammasome. We aimed to evaluate the efficacy and tolerance of anakinra in gouty patients. Methods: We conducted a multicenter retrospective review of patients receiving anakinra for gouty arthritis. We reviewed the response to treatment, adverse events and relapses. Results: We examined data for 40 gouty patients (32 men; mean age 60.0 ± 13.9 years) receiving anakinra. Mean disease duration was 8.7 ± 8.7 years. All patients showed contraindications to and/or failure of at least two conventional therapies. Most (36; 90%) demonstrated good response to anakinra. Median pain on a 100-mm visual analog scale was rapidly decreased (73.5 (70.0 to 80.0) to 25.0 (20.0 to 32.5) mm, P <0.0001), as was median C-reactive protein (CRP) level (130.5 (55.8 to 238.8) to 16.0 (5.0 to 29.5) mg/l, P <0.0001). After a median follow-up of 7.0 (2.0 to 13.0) months, relapse occurred in 13 patients after a median delay of 15.0 (10.0 to 70.0) days. Seven infectious events, mainly with long-term use of anakinra, were noted. Conclusions: Anakinra may be efficient in gouty arthritis, is relatively well tolerated with short-term use, and could be a relevant option in managing gouty arthritis when conventional therapies are ineffective or contraindicated. Its long-term use could be limited by infectious complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richette, P., & Bardin, T. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60883-7 · Cited by 915
Self-citationA pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727 · cited 5×
“Among the 40 patients, 23 received anakinra following the protocol used by So et al.[14]: 100 mg daily for three days subcutaneously.”
BackgroundMethodResultInfluential
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Self-citationGout: An old disease in new perspective – A review
Ragab, G., Elshahaly, M., & Bardin, T. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.008 · Cited by 599
Self-citationImpact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
Bardin, T., & Richette, P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0890-9 · Cited by 385
Self-citationThe role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 304
The IL-1 cytokine family and its role in inflammation and fibrosis in the lung
Borthwick, L. A. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0559-z · Cited by 294
Metadata
- Authors
- Ottaviani, S., Moltó, A., Ea, H.-K., Neveu, S., Gill, G., Brunier, L., Palazzo, E., Meyer, O., Richette, P., Bardin, T., Allanore, Y., Lioté, F., Dougados, M., & Dieudé, P.
- Venue
- Arthritis Research & Therapy
- Published
- 2013-09-17
- Volume
- 15
- Issue
- 5
- Pages
- R123-R123
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2023421402
- Cited by
- 115
- References
- 2
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.